Ran Xie

Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections

Ran Xie, Joon‐Yong Chung, Kris Ylaya et al. · Journal of Histochemistry & Cytochemistry · 2011 · 200 citations · Full text

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 149 citations · Full text

Pembrolizumab Versus Sunitinib, Urology, Genitourinary Cancer +8

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

Lori J. Wirth, Marcia S. Brose, Eric J. Sherman et al. · Journal of Clinical Oncology · 2021 · 115 citations · Full text

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel et al. · European Urology · 2021 · 81 citations · Full text

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Marcia S. Brose, Y. Panaseykin, Bhavana Konda et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 81 citations · Full text